Cargando…

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome

The prognosis of cardiorenal dysfunction induced by diabetes mellitus (DM), which belongs to cardiorenal syndrome type 5, is poor and its pathogenesis remains elusive. We have reported that CX3CL1 exacerbated heart failure and direct inhibition of CX3CL1 improved cardiac function. Emerging evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Cankun, Xuan, Wanling, Chen, Zhenhuan, Zhang, Rui, Huang, Xiaoxia, Zhu, Yingqi, Ma, Siyuan, Chen, Kaitong, Chen, Lu, He, Mingyuan, Lin, Hairuo, Liao, Wangjun, Bin, Jianping, Liao, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971671/
https://www.ncbi.nlm.nih.gov/pubmed/35370759
http://dx.doi.org/10.3389/fphar.2022.848310
_version_ 1784679686109921280
author Zheng, Cankun
Xuan, Wanling
Chen, Zhenhuan
Zhang, Rui
Huang, Xiaoxia
Zhu, Yingqi
Ma, Siyuan
Chen, Kaitong
Chen, Lu
He, Mingyuan
Lin, Hairuo
Liao, Wangjun
Bin, Jianping
Liao, Yulin
author_facet Zheng, Cankun
Xuan, Wanling
Chen, Zhenhuan
Zhang, Rui
Huang, Xiaoxia
Zhu, Yingqi
Ma, Siyuan
Chen, Kaitong
Chen, Lu
He, Mingyuan
Lin, Hairuo
Liao, Wangjun
Bin, Jianping
Liao, Yulin
author_sort Zheng, Cankun
collection PubMed
description The prognosis of cardiorenal dysfunction induced by diabetes mellitus (DM), which belongs to cardiorenal syndrome type 5, is poor and its pathogenesis remains elusive. We have reported that CX3CL1 exacerbated heart failure and direct inhibition of CX3CL1 improved cardiac function. Emerging evidence supports that CX3CL1 is involved in renal impairment. Here we attempt to clarify whether CX3CL1 might be a therapeutic target for cardiorenal dysfunction in diabetes. We found that cardiac and renal CX3CL1 protein levels were significantly increased in both streptozotocin-induced diabetic mice and in non-obese diabetic mice, and that hyperglycemia led to persistent CX3CL1 expression in the heart and kidneys even after it was controlled by insulin. In cultured cardiac and renal cells, soluble CX3CL1 accelerated mitochondrial-dependent apoptosis via activation of the RhoA/ROCK1-Bax signaling pathway and promoted fibrosis through cellular phenotypic trans-differentiation mediated by the TGF-β/Smad pathway. In the two diabetic mouse models, knockout of CX3CL1 receptor CX3CR1 or treatment with an CX3CL1 neutralizing antibody significantly improved cardiorenal dysfunction by inhibiting apoptosis, mitochondrial dysfunction, and fibrosis. Moreover, sodium glucose cotransporter 2 inhibitor canagliflozin significantly downregulated cardiac and renal CX3CL1 expression and improved cardiorenal dysfunction. These findings indicate that CX3CL1 could be a new therapeutic target for diabetes-induced cardiorenal dysfunction.
format Online
Article
Text
id pubmed-8971671
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89716712022-04-02 CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome Zheng, Cankun Xuan, Wanling Chen, Zhenhuan Zhang, Rui Huang, Xiaoxia Zhu, Yingqi Ma, Siyuan Chen, Kaitong Chen, Lu He, Mingyuan Lin, Hairuo Liao, Wangjun Bin, Jianping Liao, Yulin Front Pharmacol Pharmacology The prognosis of cardiorenal dysfunction induced by diabetes mellitus (DM), which belongs to cardiorenal syndrome type 5, is poor and its pathogenesis remains elusive. We have reported that CX3CL1 exacerbated heart failure and direct inhibition of CX3CL1 improved cardiac function. Emerging evidence supports that CX3CL1 is involved in renal impairment. Here we attempt to clarify whether CX3CL1 might be a therapeutic target for cardiorenal dysfunction in diabetes. We found that cardiac and renal CX3CL1 protein levels were significantly increased in both streptozotocin-induced diabetic mice and in non-obese diabetic mice, and that hyperglycemia led to persistent CX3CL1 expression in the heart and kidneys even after it was controlled by insulin. In cultured cardiac and renal cells, soluble CX3CL1 accelerated mitochondrial-dependent apoptosis via activation of the RhoA/ROCK1-Bax signaling pathway and promoted fibrosis through cellular phenotypic trans-differentiation mediated by the TGF-β/Smad pathway. In the two diabetic mouse models, knockout of CX3CL1 receptor CX3CR1 or treatment with an CX3CL1 neutralizing antibody significantly improved cardiorenal dysfunction by inhibiting apoptosis, mitochondrial dysfunction, and fibrosis. Moreover, sodium glucose cotransporter 2 inhibitor canagliflozin significantly downregulated cardiac and renal CX3CL1 expression and improved cardiorenal dysfunction. These findings indicate that CX3CL1 could be a new therapeutic target for diabetes-induced cardiorenal dysfunction. Frontiers Media S.A. 2022-03-18 /pmc/articles/PMC8971671/ /pubmed/35370759 http://dx.doi.org/10.3389/fphar.2022.848310 Text en Copyright © 2022 Zheng, Xuan, Chen, Zhang, Huang, Zhu, Ma, Chen, Chen, He, Lin, Liao, Bin and Liao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zheng, Cankun
Xuan, Wanling
Chen, Zhenhuan
Zhang, Rui
Huang, Xiaoxia
Zhu, Yingqi
Ma, Siyuan
Chen, Kaitong
Chen, Lu
He, Mingyuan
Lin, Hairuo
Liao, Wangjun
Bin, Jianping
Liao, Yulin
CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
title CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
title_full CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
title_fullStr CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
title_full_unstemmed CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
title_short CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
title_sort cx3cl1 worsens cardiorenal dysfunction and serves as a therapeutic target of canagliflozin for cardiorenal syndrome
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971671/
https://www.ncbi.nlm.nih.gov/pubmed/35370759
http://dx.doi.org/10.3389/fphar.2022.848310
work_keys_str_mv AT zhengcankun cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT xuanwanling cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT chenzhenhuan cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT zhangrui cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT huangxiaoxia cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT zhuyingqi cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT masiyuan cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT chenkaitong cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT chenlu cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT hemingyuan cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT linhairuo cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT liaowangjun cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT binjianping cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome
AT liaoyulin cx3cl1worsenscardiorenaldysfunctionandservesasatherapeutictargetofcanagliflozinforcardiorenalsyndrome